BMC Neurol
- KILICASLAN F, Altunisik E, Firat YE, Lule KO, et al
ABO blood group distribution in migraine patients; the relationship of phenotypes
with migraine subtypes, clinical features, and white matter lesions: a
retrospective case-control study.
BMC Neurol. 2026 Apr 2. doi: 10.1186/s12883-026-04872.
- YE W, Fan Y, Liu J, Xu X, et al
Efficacy and safety of rimegepant in Chinese women with pure menstrual migraine:
a retrospective observational study.
BMC Neurol. 2026 Apr 2. doi: 10.1186/s12883-026-04859.
Brain Res
- O'HARE L, Kalaj J, Focker J
People who play games regularly are no more robust to unpleasant images compared
to those who do not in preparation for brain research.
Brain Res. 2026;1880:150222.
Cephalalgia
- ZHUANG ZA, Thuraiaiyah J, Kokoti L, Moreno RD, et al
Migraine induced by vascular K(ATP) channel activation is independent of HCN
channel activity: A randomised controlled trial with translational validation.
Cephalalgia. 2026;46:3331024261431770.
- HAKIMZADEH Z, Chaudhry BA, Al-Khazali HM, Christensen RH, et al
Molecular triggers of migraine aura: A systematic review of human pharmacological
provocation studies.
Cephalalgia. 2026;46:3331024261429112.
- GAGO-VEIGA AB, Lopez-Rodriguez AB, Sanchez Jimenez M, Iglesias Rubio A, et al
Atogepant for migraine in real-world clinical practice: Insights from a large
multicentre study in a treatment-resistant population (GEMA project).
Cephalalgia. 2026;46:3331024261431337.
-
Corrigendum to: International Headache society evidence-based guidelines on the
use of non-invasive neuromodulation devices for the acute and preventive
treatment of migraine.
Cephalalgia. 2026;46:3331024261435762.
Headache
- GARCIA-CASTILLO MC, Sierra-Mencia A, Caronna E, Toledo-Alfocea D, et al
Evaluation of the effectiveness and safety of anti-CGRP monoclonal antibodies in
patients with migraine and autoimmune diseases: IMMUNO-CGRP study.
Headache. 2026 Apr 1. doi: 10.1111/head.70086.
- JUNG DE, Cho S, Ha WS, Shin HJ, et al
Chronotype in migraine and tension-type headache: A population study.
Headache. 2026 Mar 28. doi: 10.1111/head.70070.
- VANDERPLUYM JH
The status of status migrainosus: Exploring conceptual and operational
limitations of International Classification of Headache Disorders criteria.
Headache. 2026 Mar 27. doi: 10.1111/head.70095.
- ROBBLEE J, Smith JH, Ahmad S, Geiser R, et al
Redefining status migrainosus: A narrative review.
Headache. 2026 Mar 27. doi: 10.1111/head.70075.
- MOSKATEL LS, Slusky DJG
The state of insurance coverage of calcitonin gene-related peptide-targeted
medications and its impact on the implementation of the American Headache
Society's 2024 consensus statement: An interrupted time-series analysis.
Headache. 2026;66:801-812.
Nat Rev Neurol
- AYATA C, Hougaard A, Schiff SJ, Ferrari MD, et al
Tsunamis hiding in plain sight: spreading depression in clinical neurology.
Nat Rev Neurol. 2026 Mar 11. doi: 10.1038/s41582-026-01191.
Neurologia (Engl Ed)
- SOBRINO F, Zorro M, Bedoya MT, Ramos ML, et al
Real-world healthcare resource utilisation for migraine: analysis of an
administrative database in Colombia.
Neurologia (Engl Ed). 2026 Mar 28:502008. doi: 10.1016/j.nrleng.2026.502008.
Rev Neurol
- GINE-CIPRES E, Torres-Ferrus M, Gallardo VJ, Alpuente Ruiz A, et al
Optimizing Chronic Migraine Care: The Impact of Advanced Practice Nurse
Involvement in OnabotulinumtoxinA Administration.
Rev Neurol. 2026;81:45618.
- CERNIGLIARO F, Gallo C, Alessi G, Messina LM, et al
Pediatric Migraine Aura Status and Cortical Laminar Necrosis: A Clinical Case and
a Narrative Review.
Rev Neurol. 2026;81:47684.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016